Stock Market News

FDA staff says safety issues with Biogen’s ALS drug to not prevent approval

2023.03.20 11:56


© Reuters. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S., March 9, 2020. REUTERS/Brian Snyder

By Bhanvi Satija

(Reuters) -The U.S. health regulator’s staff said on Monday safety issues with Biogen Inc (NASDAQ:)’s drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease, should not prevent its accelerated approval.

A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday will closely scrutinize mixed efficacy data from the drug’s late-stage trial and vote on the drug’s effectiveness, and if reduction of a key protein related to the disease is enough to conclude that it may benefit ALS patients.

The drug, tofersen, failed to meet its main goal of reducing symptoms but reduced protein neurofilament levels during a late-stage study.

“Our regulations allow for regulatory flexibility to expedite the … marketing of new therapies intended to treat persons with life-threatening and severely debilitating illnesses,” the FDA’s staff said in briefing documents.

The risks related to Biogen’s drug, such as spinal cord inflammation and optic nerve swelling, observed in trial patients “are acceptable to the patient population”, the staff said.

They added that a majority of these risks may be related to the way in which the drug is administered, rather than the drug itself.

Biogen has also submitted data from an extension study to support the drug’s approval.

If approved under the FDA’s accelerated approval pathway, the drug will have to show that it provides a clinical benefit in a confirmatory trial.

The company is seeking approval for the drug in ALS patients with mutation in a gene known as superoxide dismutase 1.

Source link

Related Articles

Back to top button
bitcoin
Bitcoin (BTC) $ 97,479.12 1.06%
ethereum
Ethereum (ETH) $ 3,339.53 2.83%
tether
Tether (USDT) $ 1.00 0.09%
solana
Solana (SOL) $ 250.31 3.41%
bnb
BNB (BNB) $ 655.18 0.78%
xrp
XRP (XRP) $ 1.38 7.43%
dogecoin
Dogecoin (DOGE) $ 0.418752 6.38%
usd-coin
USDC (USDC) $ 0.999375 0.06%
cardano
Cardano (ADA) $ 0.988451 8.89%
staked-ether
Lido Staked Ether (STETH) $ 3,341.04 2.70%
tron
TRON (TRX) $ 0.207769 3.62%
avalanche-2
Avalanche (AVAX) $ 40.69 4.52%
stellar
Stellar (XLM) $ 0.509346 13.30%
the-open-network
Toncoin (TON) $ 6.08 4.71%
shiba-inu
Shiba Inu (SHIB) $ 0.000025 7.79%
wrapped-steth
Wrapped stETH (WSTETH) $ 3,961.14 2.59%
wrapped-bitcoin
Wrapped Bitcoin (WBTC) $ 97,373.09 0.64%
polkadot
Polkadot (DOT) $ 8.57 8.86%
chainlink
Chainlink (LINK) $ 17.47 2.99%
bitcoin-cash
Bitcoin Cash (BCH) $ 505.44 3.30%
weth
WETH (WETH) $ 3,341.63 2.70%
sui
Sui (SUI) $ 3.34 5.75%
pepe
Pepe (PEPE) $ 0.00002 5.21%
near
NEAR Protocol (NEAR) $ 6.80 6.17%
leo-token
LEO Token (LEO) $ 8.63 0.38%
litecoin
Litecoin (LTC) $ 95.75 6.41%
aptos
Aptos (APT) $ 12.09 8.48%
uniswap
Uniswap (UNI) $ 10.69 2.17%
wrapped-eeth
Wrapped eETH (WEETH) $ 3,519.06 2.80%
hedera-hashgraph
Hedera (HBAR) $ 0.139743 11.03%
internet-computer
Internet Computer (ICP) $ 11.20 5.46%
usds
USDS (USDS) $ 0.998841 0.24%
crypto-com-chain
Cronos (CRO) $ 0.183812 8.57%
polygon-ecosystem-token
POL (ex-MATIC) (POL) $ 0.549728 7.24%
ethereum-classic
Ethereum Classic (ETC) $ 28.14 6.88%
render-token
Render (RENDER) $ 7.93 0.70%
fetch-ai
Artificial Superintelligence Alliance (FET) $ 1.50 2.37%
bittensor
Bittensor (TAO) $ 526.57 1.66%
ethena-usde
Ethena USDe (USDE) $ 1.00 0.06%
kaspa
Kaspa (KAS) $ 0.150221 3.82%
whitebit
WhiteBIT Coin (WBT) $ 24.39 1.57%
dai
Dai (DAI) $ 0.999352 0.07%
bonk
Bonk (BONK) $ 0.000046 7.35%
arbitrum
Arbitrum (ARB) $ 0.835542 5.52%
vechain
VeChain (VET) $ 0.042125 4.15%
blockstack
Stacks (STX) $ 2.27 7.42%
filecoin
Filecoin (FIL) $ 5.49 6.05%
okb
OKB (OKB) $ 55.01 6.82%
celestia
Celestia (TIA) $ 7.64 3.10%
cosmos
Cosmos Hub (ATOM) $ 8.34 9.74%